Advances in nano drugs for cancer Chemotherapy

Current Cancer Drug Targets

Volumn 11, Issue 2, 2011, Pages 135-146

  Ali, I ^a   Rahis Uddin, ^a   Salim, K ^a   Rajora, A K ^a   Rather, M A ^a   Wani, W A ^a   Haque, A ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Cancer; Chemotherapy; Mechanism of action; Nano drugs

Indexed keywords

AD 70; ALBUMIN; ANTINEOPLASTIC AGENT; AP 5280; BLEOMYCIN; CAMPTOTHECIN; CARBON; CARBOPLATIN; CISPLATIN; COPOLYMER; CYCLODEXTRIN; DACTINOMYCIN; DAUNORUBICIN; DE 310; DENDRIMER; DEXTRAN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FCE 28068; FLUOROURACIL; INGN 401; IRON OXIDE; LESN 38; LIPOSOME; LURTOTECAN; MACROGOL; MERCAPTOPURINE; MRX 952; NANO DRUG; NANOCARRIER; NANOPARTICLE; NK 911; ONCOLIPIN; OSI 7904 L; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PNU 166945; POLYMER; PROTHECAN; THYMIDYLATE SYNTHASE INHIBITOR; TOPOTECAN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERIGENE; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CERAMICS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESEARCH; DRUG SYNTHESIS; EMULSION; HUMAN; MICELLE; NONHUMAN; PARTICLE SIZE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOSTRUCTURES;

EID: 79551631275     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911794328493     Document Type: Article

References (130)

1. Cancer control: Knowledge into action WHO Guide for effective programmes, www.who.int/cancer 2006.
2. Sikora, K.; Advani, S.; Koroltchouk, V.; Magrath, I.; Levy, L.; Pinedo, H.; Schwartsmann, G.; Tattesall, M.; Yan, S. Essential drugs for cancer therapy: A World Health Organization consultation. Ann. Oncol. 1999, 10, 385-390.
3. Leroux, J. C.; Deolker, E.; Gurmy, R.; Nenita, S. Microencapsulations, methods and industrial application. New York: Dekker 1996, pp. 537-574.
4. Allen, T. M.; Cheng, W. W.; Hare, J. I.; Laginha, K. M. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med. Chem. 2006, 6, 513-523.
5. Simon, M.; Wittmar, M.; Bakowsky, U.; Kissel, T. Self-assembling nano complexes from insulin and water-soluble branched polyesters, poly [(vinyl-3-(diethylamino)- propylcarbamate-co-(vinyl acetate)- co-(vinyl alcohol)]-graft- Poly (L-lactic acid): a novel carrier for transmucosal delivery of peptides. Bioconjug. Chem. 2004, 15, 841-849.
6. Dautzenberg, H.; Zintchenko, A.; Konak, C.; Reschel, T.; Subr, V.; Ulbrich, K. Polycationic graft copolymers as carriers for oligonucleotide delivery. Complexes of oligonucleotides with polycationic graft copolymers. Langmuir 2001, 17, 3096-3102.
7. Wang, F.; Bronich, T. K.; Kabanov, A.V.; Rauh, R. D.; Roovers. J. Synthesis and evaluation of a star amphiphilic block copolymer from poly (E-caprolactone) and poly (ethylene glycol) as a potential drug delivery carrier. J. Bioconjug. Chem. 2005, 16, 397-405.
8. Mammen, M.; Choi, S. K.; Whitesides, G. M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 1998, 37, 2754-2794.
9. Zeng, F.; Lee, H.; Allen, C. Epidermal growth factor-conjugated poly (ethylene glycol)-block-poly (ä-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjug. Chem. 2006, 17, 399-409.
10. Gossl, I.; Shu, L.; Schluter, A. D.; Rabe, J. P. Molecular structure of single DNA complexes with positively charged dendronized polymers. J. Am. Chem. Soc. 2002, 124, 6860-6865.
11. Esfand, R.; Tomalia, D. A. Poly (amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications. Drug Disco. Today 2001, 6, 427-436.
12. Gillies, E. R.; Dy, E.; Frechet, J. M. J. Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) bow-tie hybrids with tunable molecular weight and architecture. J. Am. Chem. Soc. 2002, 124, 14137-14146.
13. Chen, H. T.; Neerman, M. F.; Parrish, A. R.; Simanek, E. E. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc. 2004, 126, 10044-10048.
14. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A. K.; Thomas, T.; Mule, J.; Baker, J. R. Design and function of a dendrimer-based therapeutic nanodevice targated to tumour cells through the folate receptor. J. Pharmacol. Res. 2002, 19, 1310-1316.
15. Stiriba, S. E.; Frey, H.; Haag, R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew. Chem. Int. Ed. 2002, 41, 1329-1334.
16. Cuoung, N.V.; Hsieh, M.F. Recent advances in pharmacokinetics of polymeric excipients used in nanosized anti-cancer drugs for cancer therapy. Curr. Drug Metab. 2009, 10, 842-850.
17. Knauth, M; Egelhof, T.; Roth, S. U.; Wirtz, C.; Sartor, K. Monocrystalline iron oxide nanoparticles: possible solution to the problem of surgically induced intracranial contrast enhancement in intraoperative MR imaging. Am. J. Neuro. Radiol. 2001, 22, 99-102.
18. Alexiou, C.; Arnold, W.; Klein, R. J.; Parak, F. G.; Hulin, P.; Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lubbe, A. S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000, 60, 6641-6648.
19. Moshfeghi, A. A.; Peyman, G. A. Micro- and nanoparticulates. Adv. Drug Deliv. Rev. 2005, 57, 2047-2052.
20. Pathak, P.; Katiyar, V. K. Multi-functional nanoparticles and thier role in cancer drug delivery. J. Nanotechnol. 2007, 3, 1-17.
21. Alexis, F.; Rhee, J. W.; Richie, J. P.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 2008, 26, 74-85.
22. Yezhelyev, M. V.; Gao, X.; Xing, Y.; Al-Hajj, A.; Nie, S. O.; Regan, R. M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006, 7, 657-667.
23. Joseph, N. M.; Shrama, P. K. Nanoparticles: Drug delivery system for cancer therapy. Asian J. Pharm. 2008, 2(3), 139-140.
24. Krecter, J. Colloidal drug delivery system. New York: Dekker 1994, 219-343.
25. Majeti, N. V.; Kumar, R. Nano and microparticles as controlled Drug Delivery Devices. J. Pharm. Sci. 2000, 3, 234-258.
26. Kawasaki, E. S. Player, X. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 2005, 1, 101-109.
27. Arayne, M. S.; Sultana. N. Nanoparticles in drug delivery for the treatment of cancer. Pak. J. Pharm. Sci. 2006, 9, 256-258.
28. Chan, V. S. W. Nanomedicine: An unresolved regulatory issue. Regul. Toxicol. Pharmacol. 2006, 46, 218-224.
29. Nijhara, R.; Balakrishnan, K. Bringing nanomedicines to market: Regulorty challenges, opportunities, and uncertainties. Nanomedicine 2006, 2, 127-136.
30. Brewer, M.; Zhang, T.; Dong, W.; Rutherford, M.; Tian, Z. R. Future approaches of nanomedicine in clinical science. Med. Clin. N. Am. 2007, 91, 963-1016.
31. Morrow, K. J.; Bawa, R.; Wei, C. Recent advances in basic and clinical nanomedicine. Med. Clin. N. Am. 2007, 91, 805-843.
32. Byrne, J. D.; Betancourt, T. Active targeting scheme for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60, 1615-1626.
33. Bhattacharya, R.; Mukerjee P. Biological properties of "Nakes" metal nanoparticles. Adv. Drug Deliv. Rev. 2008, 60, 1289-1306.
34. Park, J. H.; Lee, S.; Kim, J. H.; Park, K.; Kim, K.; Known, I. C. Polymeric nanomedicine for cancer therapy. Prog. Polym. Sci. 2008, 33, 113-137.
35. Wang, Xu.; Yang, L.; Chen, Z.; Shin, D. M. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 2008, 58, 97-110.
36. Haley, B.; Frenkel. E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 2008, 26, 57-64.
37. Bawa, R. Nanobiotech 2008: Exploring global advances in nanomedicine. Nanomedicine 2009, 5, 5-7.
38. Bharali, D. J.; Khalil, M.; Gurbuz, M.; Tessa, M. S.; Mousa, S. A. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int. J. Nanomed. 2009, 4, 1-7.
39. Yokoyama, M.; Okano, T. Targeting of anti-cancer drugs with nano-sized carrier system. Nippon Rinsho 1998, 56, 3227-3234.
40. Wong, H. L.; Bendayan, R.; Andrew, M. R.; Li, Y.; Wu, X. Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59, 491-504.
41. Tanaka, T.; Decuzzi, P.; Cristofanilli, M.; Sakamoto, J. H.; Tasciotti, E; Robertson, F. M.; Ferrari, M. Nanotechnology for breast cancer therapy. Biomed. Microdevices 2009, 11, 49-63.
42. Couvreur, P.; Gruslain. L.; Lenaerts, V. Polymeric nanoparticles and microspheres. Boca Raton (FL): CRC Press 1986.
43. Koo, O. M.; Rubinstein, I.; Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 2005, 1, 193-212.
44. Hughes, A. G. Nanostructure-mediated drug delivery. Nanomedicine 2005, 1, 22-30.
45. Yang, K.; Chen, S. W.; Chen, R.; Wan, Y. M. Experimental study of cisplatin loaded polylactic acid-polyethylene glycol nanoparti cles for targeting oral carcinoma. Hua Xi Kou Qiang Yi Xue Za Zhi 2005, 23, 445-448.
46. Yu, J. Y.; Jun, Y. J.; Jang, S. H.; Lee, H. J.; Sohn, Y. S. Nanoparticulate platinum (II) anticancer drug: synthesis and characterization of amphiphilic cyclotriphosphazene-platinum(II) conjugates. J. Inorg. Biochem. 2007, 101, 1931-1936.
47. Feng, S.; Huang, G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control. Release 2001, 71, 53-69.
48. Fonsece, C.; Simoes, S.; Gaspar, R. E. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control Release 2002, 83, 273-286.
49. Yan, G. P.; Zong, R. F.; Li, L.; Fu, T.; Liu, F.; Yu, X. H. Anticancer drug-loaded nanospheres based on biodegradable amphiphilic ε-caprolactone and carbonate copolymers. Pharm. Res. 2010, 27(12), 2743-2752.
50. Yadav, S.; Van Vlerken, L. E.; Little, S. R.; Amiji, M. M. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother. Pharmacol. 2009, 63, 711-722.
51. Yang, K.; Wen, Y.; Li, L.; Wang, C.; Hou, S.; Li, C. Preparation of cucurbitacin BE polylactic acid nano-particles for targeting cervical lymph nodes. Hua Xi Kou Qiang Yi Xue Za Zhi 2001, 19, 347-350.
52. Sdthi, V.; Onyuksel, H.; Rubinstein, I. Liposomal vasoactive intestinal peptide. Methods Enzymol. 2005, 391, 377-395.
53. Koo, O.; Rubinstein, I.; Onyuksel, H. Camptothecin in sterically stabilized phopholipid micelles: a novel nanomedicine. Nanomedicine 2005, 1, 77-84.
54. Pain, D.; Das, P. K.; Ghosh, P. C. Increased circulatory half-life of liposomes after conjugation with dextran. J. Biosci. 1984, 6, 811-816.
55. Lasic, D. D.; Martin, F. J.; Gabizon, A. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biocheim. Biophys. Acta 1991, 1070, 187-192.
56. Torchilin, V. P.; Levchenko, T. S.; Whitemman, K. R. Amphiphilic poly-N-vinylpyrrolidones: Synthesis, properties and liposome surface modification. Biomaterials 2001, 75, 3035-3044.
57. Allen, T. M.; Chonn, A. Large unilamellar liposomes with low uptake in to the reticuloendothelial system. Fed. Eur. Biochem. Soc. Lett. 1987, 223, 42-46.
58. Takeuchi, H.; Kojima, H.; Yamamoto, H. Evaluation of circulation profiles of liipososmes coated with hydrophilic polymers having different molecular weights in rats. J. Control. Release 2001, 75, 83-91.
59. Peer, D.; Margalit, R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 2004, 20, 780-789.
60. Mukherjee, B.; Patra, B.; Layek, B.; Mukherjee, A. Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. Int. J. Nanomed. 2007, 2, 213-225.
61. Zhang, Y.; Zhuo, R. X. Synthesis, characterization, and in vitro 5- Fu release behavior of poly (2,2-dimethyltrimethylene carbonate)- poly(ethylene glycol)-poly(2,2-dimethyltrimethylene carbonate) nanoparticles. J. Biomed. Mater. Res. 2006, 76, 674-680.
62. Li, S.; Jiang, W.Q.; Wang, A. X.; Guan, Z. Z.; Pan, S. R. Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo. Ai Zheng 2004, 23, 381-385.
63. Xia, Y. N.; Yang, P. D.; Sun, Y. G. One-dimensional nanostructures: synthesis, characterization, and applications. Adv. Mater. 2003, 5, 353-389.
64. Shimizu, T.; Masuda, M.; Minamikawa, H. Supramolecular nanotube architectures based on amphiphilic molecules. Chem. Rev. 2005, 105, 1401-1443.
65. Tian, Z. R.; Voigt James, A.; Jun, Liu. Complex and oriented ZnO nanostructures. Nat. Mater. 2003, 2, 821-826.
66. Tian, Z. R.; Voigt, J. A.; Liu, J. Biomimetic arrays of oriented helical ZnO nanorods and columns. J. Am. Chem. Soc. 2002, 124, 12954-12955.
67. 2-based nanotubes. J. Am. Chem. Soc. 2005, 125, 12384-12385.
68. Lv, G.; He, F.; Wang, X.; Gao, F.; Zhang, G.; Wang, T.; Jiang, H.; Wu, C.; Guo, D.; Li, X.; Chen, B.; Gu, Z. Novel nanocomposite of nano Fe (3) or (4) and polylactide nanofibers for application in drug uptake and induction of cell death of leukemia cancer cells. Langmuir 2008, 24, 2151-2156.
69. Wu, J. Z.; Ho, P. C. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur. J. Pharm. Sci. 2006, 29, 35-44.
70. Lavan, D. A.; Lynn, D. M.; Langer, R. Moving smaller in drug discovery and delivery. Nat. Rev. Drug. Discov. 2002, 1, 77-84.
71. Agrawal, A.; Tripp Ralph, A.; Anderson, L. J. Real-time detectin of virus particles and viral protein expression with two-color nanoparticle probes. J. Virol. 2005, 79, 8625-8628.
72. Ijiima, S. Helical microtubules of graphitic carbon. Nature 1991, 354, 56-58.
73. Kostarelos, K.; Lacerda, L.; Partidos, C. D. Carbon nanotubemediated delivery of peptides and genes to cells: translating nanobiotechnology to therapeutics. J. Drug Deliv. Sci. Technol. 2005, 15, 41-47.
74. Freitas, R. A. What is nanomedicine? Nanomedicine 2005, 1, 2-9.
75. Harhaji, L.; Isakovic, A.; Raicevic, N.; Markovic, Z.; Todorovic-Markovic, B.; Nikolic, N.; Vranjes-Djuric, S.; Markovic, I.; Trajkovic, V. Multiple Mechanisms underlying the anticancer action of nanocrystalline fullerens. Eur. J. Pharmacol. 2007, 568, 89-98.
76. Bhadra, D.; Bhadra, S.; Jain, S.; Jain, N. K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 2003, 257, 111-124.
77. Li, S.; Wang, A.; Jiang, W.; Guan, Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer 2008, 8, 103-111.
78. Kim, J. H.; Kim, Y. S.; Park, K.; Lee, S.; Nam, H. Y.; Min, K. H.; Jo, H. G.; Park, J. H.; Choi, K.; Jeong, S. Y.; Park, R. W.; Kim, I. S.; Kim, K.; Kwon, I. C. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control Releas. 2008; 127, 41-49.
79. Verma, A. K.; Sachin, K. Novel hydrophilic drug polymer nanoconjugates of cisplatin showing long blood retention profile: its release kinetics, cellular uptake and bio-distribution. Curr. Drug Deliv. 2008, 5, 120-126.
80. Park, T. G.; Yoo, H. S. Polymer preparation. Polymer Parameters 2002, 41, 992-993.
81. Hwang, H. Y.; Kim, I. S.; Kwon, I. C.; Kim, Y. H. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J. Cont. Release. 2008, 128, 23-31.
82. Qi, L.; Xu, Z. In vivo antitumor activity of chitosan nanoparticles. Bioorg. Med. Chem. Lett. 2006, 16, 4243-4245.
83. Min, K. H.; Park, K.; Kim, Y. S.; Bae, S. M.; Lee, S.; Jo, H. G.; Park, R. W.; Kim, I. S.; Jeong, S. Y.; Kim, K.; Kwon, I. C. J. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control Release 2008, 127(3), 208-218.
84. You, S.; Li, W. Administration of nanodrugs in proper menstrual stage for maximal drug retention in breast cancer. Med. Hypotheses 2008, 71, 141-147.
85. Oh, J. M.; Choi, S. J.; Kim, S. T.; Choy, J. H. Cellular uptake mechanism of an inorganic nanovehicle and its drug conjugates: Enhanced efficacy due to clathrin-mediated endocytosis. Bioconjug. Chem. 2006, 17, 1411-1417.
86. Kim, J. Y.; Choi, S. J.; Oh, J. M.; Park, T.; Choy, J. H. Anticancer drug-inorganic nanohybrid and its cellular interaction. J. Nanosci. Nanotechnol. 2007, 7, 3700-3705.
87. Cui, D. X.; Tian, F. R.; Kong, Y. Effects of single-walled carbon nanotubes on the polymerase chain reaction. Nanotechnology 2004, 15, 154-157.
88. Gooding, J. J.; Wibowo, R.; Liu, J. Protein electrochemistry using aligned carbon nanotube arrays. J. Am. Chem. Soc. 2003, 125, 9006-9007.
89. Wang, J.; Liu, G.; Jan, M. R. Ultrasensitive electrical biosensing of proteins and DNA: carbonnanotube derived amplification of the recognition and transduction events. J. Am. Chem. Soc. 2004, 126, 3010-3011.
90. Callegari, A.; Cosnier, S.; Marcaccio, M. Functionalised single wall carbon nanotubes/polypyrrole composites for the preparation of amperometric glucose biosensors. J. Mater. Chem. 2004, 14, 807-810.
91. Gavalas, V. G.; Law, S. A.; Ball, J. C. Carbon nanotube aqueous sol-gel composites: Enzyme friendly platforms for the development of stable biosensors. Anal. Biochem. 2004, 329, 247-252.
92. Staples, M.; Daniel, K.; Cima, M. J.; Langer, R. Application of micro- and nano-electromechanical devices to drug delivery. Pharm. Res. 2006, 23, 847-863.
93. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387-6392.
94. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41,189-207.
95. Jain, K. K. Targeted drug delivery for cancer, Technol. Cancer Res. Treat. 2005, 4, 311-454.
96. Sapra, P.; Tyagi, P.; Allen, T. M. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv. 2005, 2, 369-381.
97. Charrois, G. J.; Allen, T. M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta 2004, 1663, 167-177.
98. Allen, T. M.; Cullis, P. R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818-1822.
99. Fassas, A.; Anagnostopoulos, A. The use of liposomal daunorubicin (DaunoXome) in acute yeloid leukemia. Leuk. Lymphoma 2005, 46, 795-802.
100. White, S. C.; Lorigan, P.; Margison, G. P. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-smallcell lung cancer. Br. J. Cancer 2006, 95, 822-828.
101. Rosenthal, D. I.; Yom, S. S.; Liu, L. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest. New Drugs 2002, 20, 343-349.
102. Harrington, K. J.; Lewanski, C. R.; Northcote, A. D. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 2001, 12, 493-496.
103. Guo, W.; Johnson, J. L.; Khan, S. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal. Biochem. 2005, 336, 213-220.
104. Dragovich, T.; Mendelson, D.; Kurtin, S. A Phase 2 trial of the liposomal DACH platinum LNDDP in patients with therapyrefractory advanced colorectal cancer. Cancer Chemother. Pharmacol. 2006, 58, 759-764.
105. Neville, M. E.; Boni, L. T.; Pflug, L. E. Biopharmaceutics of liposomal interleukin 2, oncolipin. Cytokine 2000, 12, 1691-1701.
106. Bayes, M.; Rabasseda, X.; Prous, J. R. Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol. 2004, 26, 639-663.
107. Pal, A.; Khan, S.; Wang, Y. F. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 2005, 25, 331-341.
108. Ciuleanu, T.; Diculescu, M.; Hoepffner, N. M. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. Invest. New Drugs 2007, 25, 385-390.
109. Clamp, A. R.; Schoffski, P.; Valle, J. W. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother. Pharmacol. 2008, 61, 579-585.
110. Seiden, M. V.; Muggia, F.; Astrow, A. A phaseII study of liposomal lurtotecan (OSI-211) inpatients with topotecan resistant ovarian cancer. Gynecol. Oncol. 2004, 93, 229-232.
111. Danhauser-Riedl, S.; Hausmann, E.; Schick, H. D. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOXOXD). Invest. New Drugs 1993, 11, 187-195.
112. Matsumura Y. Micelle carrier system in clinical trial. Nippon Rinsho 2006, 64, 316-321.
113. Matsumura, Y.; Hamaguchi, T.; Ura, T. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 2004, 91, 1775-1781.
114. Gradishar, W. J. Albumin-bound nanoparticle paclitaxel. Clin. Adv. Hematol. Oncol. 2005, 3, 348-349.
115. Ferrari, M. Experimental therapies: Vectoring siRNA therapeutics into the clinic. Nat. Rev. Clin. Oncol. 2010, 7, 485-486.
116. Gradishar, W. J.; Tjulandin, S.; Davidson, N. Phase III trial of nanoparticles albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23, 7794-7803.
117. Greenwald, R. B.; Choe, Y. H.; McGuire, J.; Conover, C. D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 2003, 55, 217-250.
118. Rowinsky, E. K.; Rizzo, J.; Ochoa, L. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. 2003, 21, 148-157.
119. Boddy, A. V.; Plummer, E. R.; Todd, R. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. 2005, 11, 7834-7840.
120. Albain, K. S.; Belani, C. P.; Bonomi, P. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapynaive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin. Lung Cancer 2006, 7, 417-419.
121. Shiose, Y.; Kuga, H.; Yamashita, F.; Hashida, M. Quantitative acid hydrolysis of DE 310, a macromolecular carrier system for the camptothecin analog DX-8951f. J. Pharm. Biomed. Anal. 2007, 43, 1290-1296.
122. Soepenberg, O.; de-Jonge, M. J.; Sparreboom, A. Phase I and pharmacokinetic study of DE- 310 in patients with advanced solid tumors. Clin. Cancer Res. 2005, 11, 703-711.
123. Ochi, Y.; Shiose, Y. Y.; Kuga, H.; Kumazawa, E. A possible mechanism for the long- lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. Cancer Chemother. Pharmacol. 2005, 55, 323-332.
124. Thomson, A. H.; Vasey, P. A.; Murray, L. S. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br. J. Cancer 1999, 81, 99-107.
125. Bilim, V. Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr. Opin. Mol. Ther. 2003, 5, 326-330.
126. Seymour, L. W.; Ferry, D. R.; Anderson, D. Hepatic drug targeting: phase I evaluation of polymer- bound doxorubicin. J. Clin. Oncol. 2002, 20, 1668-1676.
127. Rademaker-Lakhai, J. M.; Terret, C.; Howell, S. B. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenousinfusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. 2004, 10, 3386-3395.
128. Terwogt, M.; Jetske, M.; Huinink, T. B.; Wim, W. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001, 12, 315-323.
129. Bissett, D.; Cassidy, J.; de-Bono, J. S. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer 2004, 91, 50-55.
130. Sarapa, N.; Britto, M. R.; Speed, W. Assessment of normal and tumor tissue uptake of MAGCPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother. Pharmacol. 2003, 52, 424-430.